Measles Virus for Immunovirotherapy of Cancer
DKFZ Deutsches Krebsforschungszentrum
Viral therapy holds the promise for an effective and poor in side effects way of cancer treatment. During the last years several groundbreaking inventions have led to sentential improvements in therapy outcome of several different viral systems. The invention discloses a measles virus based tumour therapy.
The invention depicts a measles virus based therapeutic candidate for solid cancers and has been successfully tested in an in vivo model of melanoma.
- Measles virus based cancer therapy
- Virus expressing singe chain antibodies against CTLA-4 or PD-L1
- Proven effectiveness in a syngeneic immunocompetent murine melanoma model
The technology has successfully been tested in animal in vivo validated studies.
A recombinant virus of the family Paramyxoviridae virus encoding single chain antibodies against CTLA-4 or PD-L1 in alone or in combination with an immune stimulatory molecule like GM-CSF. The virus has been shown to dig increase the survival time of animals tested in a syngeneic immunocompetent murine melanoma model significantly.
Applications and Commercial Opportunity
DKFZ is looking for a partner to promote the invention towards clinical application.
The investigators are Guy Ungerechts, Christine Engeland, Sascha Bossow (all DKFZ Department of Translational Oncology, G100)
DKFZ has filed a US provisional application US 61/944,353 with a priority date February 25th in 2014.
No other public information is currently available, but further information (speaking with the inventor) is available under a signed Confidential Disclosure Agreement (CDA).
“Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine.” by Grossardt C. et al. in Hum Gene Ther. 2013 Jul; 24(7):644-54